The Multiple Myeloma Hub spoke to Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paolo, BR. We asked, What is the impact of belantamab mafodotin (belamaf) on quality of life (QoL) in patients with multiple myeloma (MM)? 

Hungria provided insights into the mechanism of action of belamaf, its efficacy and safety in heavily pre-treated patients, and the latest findings from the phase III DREAMM-7 (NCT04246047) study. Hungria discussed how belamaf in combination with bortezomib and dexamethasone (BelaVd) impacts disease progression, survival, and patient-reported outcomes compared to daratumumab with Vd (DaraVd). This discussion also evaluated the safety profile of belamaf, including ocular side effects and their impact on QoL.

Key learnings

• Belamaf is an antibody–drug conjugate that targets the B-cell maturation antigen on malignant plasma cells.
• Belamaf has previously demonstrated promising anti-myeloma activity and a manageable safety profile as a sole agent in patients with heavily pre-treated MM.

DREAMM-71,2

• DREAMM-7 is a phase III, randomized study evaluating BelaVd vs DaraVd in patients with relapsed/refractory MM.
• A statistically significant benefit in progression-free survival, overall survival, duration of response, and measurable residual disease negativity were observed with BelaVd.
• Patients reported stable quality of life, physical functioning, fatigue, and disease symptoms, with no significant differences between treatment arms.
• Ocular toxicities were more common during the initial phase of treatment but generally improved as dosing frequency was reduced, highlighting dose modification as an effective strategy to manage these effects.
• Among patients who experienced a clinically meaningful decline in visual acuity, overall QoL remained comparable to those treated with DaraVd.
• BelaVd has a limited impact on health-related QoL, supporting its potential as a new standard of care treatment for relapsed/refractory MM.

This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

The Multiple Myeloma Hub spoke with Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, What is the impact of elranatamab on quality of life (QoL) in relapsed/refractory multiple myeloma (RRMM)?

Mohty discussed the impact of elranatamab on QoL in patients with RRMM, highlighting its benefits in symptom relief, mobility, and overall well-being. Mohty also addressed the associated risk of cytokine release syndrome (CRS), neurotoxicity, and infections, concluding with the latest clinical trial data and emphasizing the need for ongoing research to optimize the role of elranatamab and other bispecific antibodies in patient care.

Key learnings

• Overall, elranatamab has positively impacted QoL in many patients with RRMM by providing rapid symptom relief, reducing bone pain and fatigue, improving mobility, and decreasing healthcare visits.
• Better disease control also contributes to improved psychological well-being.
• These benefits ultimately enhance daily functioning and overall well-being, allowing patients to resume their daily activities.
• Adverse events are a concern; however, the implementation of step-up dosing helps to reduce the risks of severe CRS and neurotoxicities.
• The risk of infections remains significant. However, mitigation strategies such as prophylactic antivirals, antifungals, and intravenous immunoglobulin administration can help preserve QoL.
• Clinical trial data from the MagnetisMM-3 (NCT04649359) trial support these findings, demonstrating improved patient-reported outcomes in global health status, functional ability, and symptom management.
• Ongoing trials aim to further clarify the role of elranatamab and other bispecific antibodies in enhancing QoL.

This educational resource is independently supported by Pfizer. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium entitled ‘Sequencing immune-based therapies in B-cell malignancies’.

Here the Multiple Myeloma Hub is pleased to share the session: Next wave of immune-based therapies: What you need to know, which focused on relapsed/refractory (R/R) multiple myeloma (MM) and was presented by Krina Patel, MD Anderson Cancer Center, Houston, US.

This activity was supported through an educational grant from Bristol Myers Squibb.

Hosted on Acast. See acast.com/privacy for more information.